BMP2-derived peptide

Name: BMP2-derived peptide
Brand: MedChemExpress
SKU: HY-P5832
Rating: 4.5 (1 reviews)

Cat. No.: HY-P5832 Purity: 98.04%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

BMP2-derived peptide Chemical Structure

CAS No. : 836606-84-9

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All RUNX Isoform Specific Products:

View All Isoforms

RUNX1 RUNX2

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

RUNX2

In Vitro

When covalently conjugated with mesoporous silica nanoparticles (MSNs) (forming MSNs-pep), the BMP2-derived peptide (50-100 μg/mL; 24-48 h) significantly enhances the cellular uptake of the nanoparticles by rat bone marrow mesenchymal stem cells (BMSCs)^[1].
BMP2-derived peptide (25-100 μg/mL; 7-21 days), when covalently conjugated to mesoporous silica nanoparticles (MSNs) (i.e., MSNs-pep), significantly upregulates alkaline phosphatase (ALP) activity in rat bone marrow mesenchymal stem cells (BMSCs) after 21 days of incubation^[1].
PLAF/PLEOF nanoparticles conjugated with BMP2-derived peptide (2 mg/mL; 2-24 h) are taken up by rat bone marrow stromal cells in a time-dependent manner in osteogenic medium, and the uptake level at 6 h of incubation is significantly higher than that of non-conjugated nanoparticles^[2].
Rat bone marrow stromal cells treated with BMP2-derived peptide-grafted PLAF/PLEOF nanoparticles (200 ng/mL; 7-21 d) in osteogenic medium exhibit obvious aggregation and differentiated morphology after 21 days of incubation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:	rat bone mesenchymal stem cells (BMSCs)
Concentration:	50 μg/mL (equivalent to ~400 ng/mL BMP2-derived peptide)
Incubation Time:	21 days
Result:	Induced significantly higher RUNX2 expression compared to osteoconductive medium alone. Induced significantly higher osteocalcin expression compared to osteoconductive medium alone.

Cell Differentiation Assay^[2]

Cell Line:	Rat bone marrow stromal cells
Concentration:	200 ng/mL
Incubation Time:	7, 21 days (37 °C in 5% CO₂)
Result:	Induced high levels of aggregation in rat bone marrow stromal cells after 21 days of incubation, forming star and circular patterns characteristic of osteogenic differentiation.

In Vivo

MSNs functionalized with BMP2-derived peptide (100 μg per implant; intramuscular injection; single administration) induce ectopic osteogenesis in rats receiving intramuscular implantation^[1].
BMP2-derived peptide (100 μg; intramuscular implantation; single administration) induces ectopic bone formation in male Sprague-Dawley rats at 3 weeks post-administration^[3].
BMP2-derived peptide (100 μg + 20 μg Dexamethasone (HY-14648); intramuscular implantation; single administration) induces more ectopic bone formation in male Sprague-Dawley rats at 3 weeks post-administration^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley rat with Ectopic bone formation (SD) (4-week-old, male)^[3]
Dosage:	100 µg
Administration:	intramuscular implantation; single dose
Result:	Showed calcified deposits (white shadows) in the area surrounding the implanted region via CT imaging. Confirmed the presence of newly formed bone at the implant site via HE staining.

Animal Model:	Sprague-Dawley rat with Ectopic bone formation (SD) (4-week-old, male)^[3]
Dosage:	100 µg (BMP2-derived peptide); 20 µg (DEX)
Administration:	intramuscular implantation; single dose
Result:	Showed more obvious mineralization (calcified deposits) in the area surrounding the implanted region via CT imaging compared to the MSNs-pep group. Confirmed a greater amount of newly formed bone at the implant site via HE staining compared to the MSNs-pep group.

Molecular Weight

2117.48

Formula

C₉₇H₁₆₅N₂₃O₂₉

CAS No.

836606-84-9

Appearance

Solid

Color

White to off-white

Sequence

Lys-Ile-Pro-Lys-Ala-Ser-Ser-Val-Pro-Thr-Glu-Leu-Ser-Ala-Ile-Ser-Thr-Leu-Tyr-Leu-NH2

Sequence Shortening

KIPKASSVPTELSAISTLYL-NH2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (47.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.4723 mL	2.3613 mL	4.7226 mL
5 mM	0.0945 mL	0.4723 mL	0.9445 mL
10 mM	0.0472 mL	0.2361 mL	0.4723 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 98.04%

Select Batch:

Data Sheet (284 KB) SDS (252 KB)

COA (255 KB) LCMS (99 KB) Elemental Analysis Report (114 KB)

Handling Instructions (2659 KB)

References

[1]. Zhou X, et al. BMP-2 Derived Peptide and Dexamethasone Incorporated Mesoporous Silica Nanoparticles for Enhanced Osteogenic Differentiation of Bone Mesenchymal Stem Cells. ACS Appl Mater Interfaces. 2015;7(29):15777-15789.

[2]. Mercado AE, et al. Effect of grafting BMP2-derived peptide to nanoparticles on osteogenic and vasculogenic expression of stromal cells. J Tissue Eng Regen Med. 2014;8(1):15-28.

[3]. Chen Y, et al. Zero-order controlled release of BMP2-derived peptide P24 from the chitosan scaffold by chemical grafting modification technique for promotion of osteogenesis in vitro and enhancement of bone repair in vivo. Theranostics. 2017;7(5):1072-1087. Published 2017 Feb 27.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.4723 mL	2.3613 mL	4.7226 mL	11.8065 mL
	5 mM	0.0945 mL	0.4723 mL	0.9445 mL	2.3613 mL
	10 mM	0.0472 mL	0.2361 mL	0.4723 mL	1.1806 mL
	15 mM	0.0315 mL	0.1574 mL	0.3148 mL	0.7871 mL
	20 mM	0.0236 mL	0.1181 mL	0.2361 mL	0.5903 mL
	25 mM	0.0189 mL	0.0945 mL	0.1889 mL	0.4723 mL
	30 mM	0.0157 mL	0.0787 mL	0.1574 mL	0.3935 mL
	40 mM	0.0118 mL	0.0590 mL	0.1181 mL	0.2952 mL